Skip to main content
. 2021 Apr 15;11(4):1697–1708.

Figure 1.

Figure 1

Tolerance and efficacy of CAN017 in ES0199 and ES0195 PDX models. A. Body weights of mice during treatment. Data were presented as means ± SDs. B. Tumor growth curves showed the in vivo activity of CAN017 in ES0199 and ES0195 PDX models treated with vehicle control, hIgG control (20 mg/kg) and CAN017 (20 mg/kg) every 3 days. Data were indicated as means ± SDs. The anti-tumor activity was depicted by TGI with 105.92% and 44.86% in ES0199 and ES0195 PDX models, respectively. C. Kaplan-Meier graph showed the probability of tumor progression-free mice in ES0199 and ES0195 PDX models during the treatment. **P < 0.01; ns, not significant by log-rank test.